Group One Trading, L.P. Obs Eva Sa Transaction History

Group One Trading, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$0.14 - $0.21 $10,647 - $15,971	-76,055 Reduced 67.36%	36,859 $5,000
Q3 2022 Nov 09, 2022	SELL	$0.14 - $1.83 $6,496 - $84,912	-46,400 Reduced 29.12%	112,914 $16,000
Q2 2022 Aug 11, 2022	BUY	$1.34 - $2.08 $79,914 - $124,047	59,638 Added 59.83%	159,314 $257,000
Q1 2022 May 12, 2022	SELL	$1.1 - $2.17 $91,032 - $179,582	-82,757 Reduced 45.36%	99,676 $151,000
Q4 2021 Feb 11, 2022	BUY	$1.99 - $3.1 $253,008 - $394,134	127,140 Added 229.94%	182,433 $363,000
Q3 2021 Nov 12, 2021	SELL	$2.47 - $3.34 $21,681 - $29,318	-8,778 Reduced 13.7%	55,293 $172,000
Q2 2021 Aug 10, 2021	BUY	$2.56 - $3.35 $121,088 - $158,455	47,300 Added 282.03%	64,071 $194,000
Q1 2021 May 12, 2021	BUY	$2.01 - $5.05 $31,024 - $77,946	15,435 Added 1155.31%	16,771 $55,000
Q4 2020 Feb 10, 2021	SELL	$1.89 - $2.55 $17,388 - $23,460	-9,200 Reduced 87.32%	1,336 $3,000
Q3 2020 Nov 12, 2020	BUY	$2.46 - $6.15 $25,918 - $64,796	10,536 New	10,536 $26,000

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.